We evaluated the analytical performance of a newly developed electrochemiluminescence immunoassay for everolimus and sirolimus compared to that of liquid chromatography-tandem mass spectrometry (LC-MS/MS).
| INTRODUC TI ON
Everolimus and sirolimus are widely used as immunodepressants to prevent rejection in patients who have undergone solid organ transplantation. 1-3 Thesedrugshavenarrowtherapeuticrangesof3-8ng/ mL for everolimus and 4-12 ng/mL for sirolimus. 4 Additionally,immunodepressants show pharmacokinetic variability and can cause severe toxicity including infection, bone marrow suppression, and metabolic effects. 4, 5 Therefore, both accurate measurement of their concentrations in the blood and prompt therapeutic drug monitoring are crucial for maximizing their therapeutic effects and minimizing toxicity. [6] [7] [8] [9] [10] Because liquid chromatography-tandem mass spectrometry (LC-MS/MS) is known to have low interference, LC-MS/MS is currently used as a gold standard method for determining the concentrations of everolimus and sirolimus. [11] [12] [13] However, broad adoption of LC-MS/MS in clinical laboratories has some limitations including difficulties in automating the test process and high cost of the instrument. 14, 15 Therefore, LC-MS/MS must be combined with other methods such as automated immunoassays, which are cost-effective, simple, and rapid. The Elecsys ® Everolimus and Sirolimus assays manufactured by Roche Diagnostics (Basel, Switzerland) were recently developed for measuring the concentration of everolimus and sirolimus based on automated electrochemiluminescence immunoassays.
In this study, we evaluated the analytical performance of the Elecsys ® Everolimus and Sirolimus assays. Particularly, we determined whether Elecsys ® Everolimus and Sirolimus assays can be used as an alternative method to LC-MS/MS for measuring immunodepressant levels. By comparing the results of the Elecsys ® Everolimus and Sirolimus assays to those of LC-MS/MS, we confirmed the accuracy of the automated electrochemiluminescence immunoassays using samples collected from patients who underwent organ transplantation and were treated with everolimus or sirolimus.
| MATERIAL S AND ME THODS
TheethicscommitteeofAsanMedicalCenterapprovedtheuseof patientdata(2018-0125).
| Samples
A total of 120 EDTA whole blood samples were collected from SeptembertoNovember2017inAsanMedicalCenter.Foreverolimusevaluation,studysubjectsconsistedof60patients(51males and9females)withameanageof56.1years.Theyhadreceived a liver transplantation (n = 51) or heart transplantation (n = 9). For sirolimus evaluation, study subjects consisted of 60 patients (33 males and 27 females) with a mean age of 52.3 years. They had received a kidney transplantation (n = 50), heart transplantation (n = 5), or other organ transplantations (n = 5). After collection, thesampleswerestoredat−20°Cuntilthetimeofanalysis.Drug concentrations were equally distributed based on clinically significant concentrations including the therapeutic range: everolimus:
3-8ng/mL;sirolimus:5-15ng/mL. 4, 16 Quality control (QC) materials (PreciControl ISD Elecsys, Roche Diagnostics) were used to evaluate precision. (Chromsystems Instruments & Chemicals) was used as a QC material.
| Electrochemiluminescence immunoassays

| LC-MS/MS assays
The samples were eluted and graduated with a mobile phase composed of ammonium acetate, formic acid, and water or methanol. Everolimus and sirolimus were detected in positive-ion multiple-reaction-monitoring mode, and the following precursor/production pairs were detected as1,220.8>1,203.8m/zforeverolimusand821.5>768.5m/zfor sirolimus. The data were quantified using a six-point standard curve.
The limit of detection values were 0.2 and 0.3 ng/mL for everolimus and sirolimus, respectively. 17 The limit of quantitation values were 1.2 and 1.1 ng/mL for everolimus and sirolimus, respectively. 17
| Precision
For precision evaluation, low, medium, and high concentrations of QC materials were used. Each QC material was measured in duplicate on the same day at more than 2-hour intervals, and the measure- EP05-A2. 18 The acceptance criteria were based on the recom-
mendations of the International Association of Therapeutic Drug
Monitoring and Clinical Toxicology expert consensus group. 19 
| Linearity and recovery
AccordingtoCLSIEP06-A,linearityandrecoverywereevaluated. 20 Patient samples at high and low concentrations were serially diluted to produce five different concentrations. The Elecsys ® Everolimus and Sirolimus assays were performed four times on the same day. The means of the concentrations were compared to the expected values.
| Comparison
Each measurement was performed within 4 hour in duplicate ac-cordingtotheCLSIEP9-A3. 21 Passing-Bablok analysis. 22 Additionally,thedifferenceinthetwoas-sayswasidentifiedusingaBland-Altmanplot.
| Carryover
Afterpatientsamplesathighconcentrations(H1,H2,H3,andH4)
were measured, low-concentration samples (L1, L2, L3, and L4) were 
| Precision
The results of precision evaluation are presented in 
| Linearity and recovery
The results of linearity evaluation are presented in Figure 1 
| Correlation with LC-MS/MS
The results of correlation analysis between the automated electrochemiluminescence immunoassays and LC-MS/MS are shown in 
| Carryover
Carryoveranalysisshowedavalueof−1.09%intheeverolimusassay and−0.12%inthesirolimusassay.
| D ISCUSS I ON
In this study, we evaluated the overall analytic performance of the 23 Matrix effect, known to be caused by other components present in samples, can greatly affect the accuracy of immunoassays. 24 Additionally,biasmaybealsocausedbyinaccurate calibration before measurement, non-specific binding, or cross-reactivity between immunoassays. 25, 26 For example, the major metabo-litesofeverolimussuchas46-hydroxy,24-hydroxyeverolimus,and 25-hydroxyeverolimuscancauseapproximately2%-72%cross-reactivities in the everolimus immunoassay. 27, 28 Moreover, sirolimus and its major metabolites can occur cross-reactivity in the everoli-musimmunoassaybecauseoftheir46%structuralsimilarity. 29 We confirmed that the Elecsys ® Everolimus and Sirolimus assays show a generally acceptable correlation with the LC-MS/MS method. However, some significant differences were observed at a high concentration (>2-fold the therapeutic range), which has not been frequently observed clinically. Therefore, clinicians may use Clinically, the sirolimus has been more frequently used than everolimus in kidney transplantation due to its longer elimination half-life, which makes clinicians easier to manage in medical practice. 32 On the other hand, the everolimus has been mainly used for liver transplantation because the use of sirolimus in the early post-transplant period has been influenced by the high incidence of hepatic artery thrombosis and decreased graft survival. 33 Fortunately, the previous report showed that unlike other immunoassays, the Elecsys ® Everolimus assay showed similar results in kidney, liver, and heart transplantations. 1
In conclusion, the Elecsys ® Everolimus and Sirolimus assays are useful for determining the concentrations of immunodepressants based on automatized electrochemiluminescence immunoassays.
We confirmed the good analytical performance of the assays including precision, linearity, and carryover effects. Particularly, high correlations with the gold standard method (LC-MS/MS) suggest that these assays can be used as alternatives to LC-MS/MS in clinical laboratories without mass spectrometry instruments. The Elecsys ® Everolimus and Sirolimus assays are useful and practical methods for monitoring the concentrations of everolimus and sirolimus in the blood of patients who have undergone organ transplantation.
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